metaPreg - Isradipine (versus exposed to other treatments) during pregnancy

Isradipine (versus exposed to other treatments)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Maternal consequences
2 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
4 non statistically significant endpoints reported in only one study